Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $16.18 USD
Change Today -0.15 / -0.92%
Volume 40.7K
As of 8:10 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

astellas pharma inc-unsp adr (ALPMY) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/24/15 - $16.99
52 Week Low
04/28/14 - $10.87
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

astellas pharma inc-unsp adr (ALPMY) Related Businessweek News

View More BusinessWeek News

astellas pharma inc-unsp adr (ALPMY) Details

Astellas Pharma Inc. manufactures, markets, and imports/exports pharmaceutical products worldwide. The company focuses on the therapeutic areas of urology, immunology and infectious diseases, oncology, neuroscience, and diabetes mellitus complications and kidney diseases. The company offers immunosuppressants, including Prograf, and Advagraf/ Graceptor/ ASTAGRAF XL; Vesicare and Betanis/Myrbetriq/BETMIGA for overactive bladder treatment; and Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia. It also provides Funguard/MYCAMINE, a candin antifungal agent; Protopic for atopic dermatitis; Eligard, XTANDI, and Gonax for prostate cancer treatment; Micardis, including Micombi and Micamlo BP for hypertension; Celecox, an anti-inflammatory agent; Symbicort for adult bronchial asthma and chronic obstructive pulmonary disease; Geninax for oral quinolone antibiotic; Bonoteo for osteoporosis; Cimzia for the treatment of adult patients with rheumatoid arthritis; and Suglat for type two diabetes treatments. In addition, the company offers Lipitor products for the treatment of hypercholesterolemia; Gaster for peptic ulcers and gastritis; Myslee for insomnia; Seroquel for schizophrenia; Regnite for restless legs syndrome; Kiklin for hyperphatemia treatments, as well as Lexiscan and Adenoscan, which are pharmacologic stress agents; and Tarceva for the treatment of lung and pancreatic cancers. Further, it provides Acofide for functional dyspepsia; Bisono Tape, a transdermal hypertension medication; diarrhea-predominant OD tablets; and dificlir for clostridium difficile infections. It has a strategic alliance with Amgen Inc. and ClearPath Development Company; and collaborative agreements with Immuno-Biological Laboratories Co., Ltd., Cytokinetics, Inc., Mitokyne, Inc., QIAGEN N.V., Dana-Farber Cancer Institute, and Ventana Medical Systems, Inc. The company was founded in 1923 and is headquartered in Tokyo, Japan.

17,649 Employees
Last Reported Date: 06/18/14
Founded in 1923

astellas pharma inc-unsp adr (ALPMY) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥170.0M
Compensation as of Fiscal Year 2014.

astellas pharma inc-unsp adr (ALPMY) Key Developments

Astellas Pharma, Inc. Announces Consolidated Earnings Forecasts for Full Basis and Core Basis for the Fiscal Year Ended March 31, 2015

Astellas Pharma Inc. announced consolidated earnings forecasts for full basis and core basis for the fiscal year ended March 31, 2015. For the year, on full basis, the company expects sales of JPY 1,247,259 million, operating profit of JPY 185,663 million, profit before tax of JPY 135,856 million, profit for the year of JPY 135,856 million and profit attributable to owners of the parent of JPY 135,856 million or earnings per share of JPY 61.50. Sales are expected to exceed the previous forecast due to global expansion of XTANDI and OAB treatments Vesicare and Betanis/Myrbetriq/BETMIGA. On core basis, the company expects sales of JPY 1,247,259 million, core operating profit of JPY 216,500 million, core profit for the year of JPY 153,244 million or core earnings per share of JPY 69.37 compared to sales of JPY 1,210,000 million, core operating profit of JPY 210,000 million, core profit for the year of JPY 154,000 million or earnings per share of JPY 69.65 reported in previous forecast.

Astellas Pharma, Inc., Board Meeting, Apr 23, 2015

Astellas Pharma, Inc., Board Meeting, Apr 23, 2015. Agenda: To decide candidates for Director and Audit & Supervisory Board Member to be newly elected at the Ordinary General Meeting of Shareholders scheduled for June 17, 2015.

Astellas Pharma and Potenza Therapeutics Partner to Build Portfolio of Immuno-Oncology Therapeutics

Astellas Pharma Inc. and Potenza Therapeutics, Inc. announced an exclusive research and development collaboration. The goal of the collaboration is to advance a portfolio consisting of programs with novel mechanisms of action targeting immune checkpoint pathways, co-stimulatory signals and regulatory T cells. The agreement includes an option that allows for the future acquisition of Potenza by Astellas on pre-determined terms at the end of the collaboration. Under the terms of the collaboration agreement, Potenza will lead drug discovery activities and deliver development candidates to Astellas. Astellas will be responsible for clinical development activities and commercialization. Specific financial terms will not be disclosed, but include an equity investment, option fee, research funding, and potential future acquisition and milestone payments.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALPMY:US $16.18 USD -0.15

ALPMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $70.37 USD -0.77
Becton Dickinson and Co $142.04 USD -2.29
Boston Scientific Corp $17.98 USD -0.36
CSL Ltd A$93.73 AUD -1.55
Mylan NV $71.72 USD -4.34
View Industry Companies

Industry Analysis


Industry Average

Valuation ALPMY Industry Range
Price/Earnings 34.8x
Price/Sales 3.6x
Price/Book 3.1x
Price/Cash Flow 23.4x
TEV/Sales 3.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTELLAS PHARMA INC-UNSP ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at